Form 4: Marimed CEO Levine Converts RSUs, Adjusts Holdings

Marimed Inc.'s President and CEO, Jon R. Levine, reported the conversion of Restricted Stock Units into common stock and a subsequent tax-related disposition, adjusting his direct and indirect beneficial ownership.

Summary

• Jon R. Levine, President and CEO, Director, and 10% Owner of Marimed Inc. (MRMD), reported changes in his beneficial ownership.
• Acquired 93,750 shares of common stock through the conversion of Restricted Stock Units (RSUs) on November 29, 2025.
• Disposed of 27,516 shares of common stock on November 29, 2025, to cover tax withholding obligations related to the RSU vesting, at a price of $0.0896 per share.
• Following these transactions, direct beneficial ownership stands at 21,072,715 shares of common stock.
• Indirect beneficial ownership remains 6,684,640 shares held by the Jon Levine Family Trust, for which Mr. Levine disclaims beneficial ownership.
• Mr. Levine retains 187,500 unvested Restricted Stock Units, which were granted on November 29, 2024.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation events (RSU vesting and tax-related disposition). While the executive's direct holdings decreased slightly due to tax withholding, the overall event is neutral to slightly positive as it represents earned compensation and continued significant ownership.

Positives

• The conversion of RSUs indicates a vesting event, representing earned compensation for the executive.
• The executive continues to hold a significant number of shares (over 21 million directly and 6.6 million indirectly), indicating strong alignment with shareholder interests.

Negatives

• A portion of the vested shares (27,516) was sold to cover tax obligations, which, while a common practice, results in a reduction of direct ownership.

Future Outlook

Remaining Restricted Stock Units (187,500) are scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.

Industry Context

This filing is a routine insider transaction report, common across all industries for executives receiving equity compensation. It reflects standard compensation practices and tax management strategies rather than specific industry trends.

Comparison to Industry Standards

• The RSU conversion and subsequent tax-related disposition are standard practices for executive equity compensation across publicly traded companies.
• The withholding of shares for tax purposes is a common method to satisfy tax obligations upon vesting, aligning with typical industry compensation structures.
• No specific comparable companies or projects are mentioned in this transactional filing.

Stakeholder Impact

• Shareholders: The executive's continued significant ownership aligns interests with shareholders. The slight reduction in direct ownership due to tax withholding is a minor, routine event.
• Employees: The vesting of RSUs is a standard form of executive compensation, which can be a positive signal for employee incentive programs.

Next Steps

• Future vesting of 187,500 remaining Restricted Stock Units in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and a subsequent tax-related disposition. It does not contain information that would fundamentally alter the investment thesis for Marimed Inc. The executive maintains a substantial ownership stake, which is generally a positive for alignment with shareholder interests. Therefore, an investor would likely maintain their current position based solely on this filing.

Keywords

Marimed Inc., MRMD, Jon R. Levine, SEC Form 4, Beneficial Ownership, Restricted Stock Units, RSU Conversion, Insider Trading, Executive Compensation, Stock Holdings